N/A N=41 Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
Breast Cancer · Breast Tumors · Cancer of Breast
Primary: Pathologic Response Based on Miller-Payne Grading System — 4; 1; 3; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=397 Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Lung Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) — 8.9; 5.0…
N/A N=23 Novel Protection Against Potential Brain, Hearing and Vision Injury During Blast Wave Exposure
Concussion, Mild
Primary: Blast Explosive Waves Experienced During the Training — 4.11; 4.29; 4.20; 4.0 number of blasts
Phase 2 N=370 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Investigator's Global Assessment (IGA) Responders at Day 29 Following Treatment With ASB17061 Capsules or Placebo in Adults With Atopic Dermatitis — 20; 21…
Phase 3 N=448 Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension
Cataract
Primary: Cure at Day 14 — 94; 97; 24; 50 Participants — p=0.0005
N/A N=126 Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic Fatty Liver Disease
Primary: Hematic Levels of Hepatic Enzymes AST — 35.4; 37.5; 31.6; 31.2 IU/L — p=<0.05
Phase 2 N=47 Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Propionic Acidemia, Type I and/or Type II · Methylmalonic Acidemia · Carbamoyl-Phosphate Synthase I Deficiency Disease
Primary: Time to the Primary Outcome (Earlier of Ammonia <50 µmol/L or Hospital Discharge) — 1.37; 0.79 Hazard Ratio
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
Phase 3 N=8,246 Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)
Type 2 Diabetes Mellitus
Primary: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke])…
Phase 2 N=48 Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
Cardiac Arrest
Primary: Coenzyme Q10 Plasma Levels — 185; 207; 113; 441 ng/mL
Phase 2 N=713 A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
Respiratory Tract Infection
Primary: Percentage of Participants Achieving Anti-Tetanus Toxoid (TTd) Antibody Concentrations of Greater Than or Equal to (>=) 0.1 International Units Per Milliliter (IU/mL) at…
N/A N=113 Racial/Ethnic Differences in Microneedle Response
Healthy
Primary: Micropore Closure Time — 44.1; 48.0; 66.5; 50.1 hours
Phase 2 N=35 A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
Aplastic Anemia
Primary: Proportion of Subjects Achieving a Platelet Response at Week 9 — 0; 0; 3; 7 Participants
N/A N=151 Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
Cardiovascular Disease · Preeclampsia · Hypertension
Primary: Eating Habits Confidence Survey — 4.2; 4.5 units on a scale
Phase 4 N=200 Efficacy of Naproxen-codeine, Naproxen+Dexamethasone, and Naproxen on Myofascial Pain
Temporomandibular Disorder
Primary: Pain Evaluation — 6.38; 6.93; 5.76; 5.49 score on a scale